Should I buy or sell Surmodics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRDX shares. View SRDX analyst ratings or view top-rated stocks .

What is Surmodics' stock price target for 2024?

2 equities research analysts have issued twelve-month target prices for Surmodics' stock. Their SRDX share price targets range from $47.00 to $71.00. On average, they expect the company's stock price to reach $59.00 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price. View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts .

How have SRDX shares performed in 2024?

Surmodics' stock was trading at $36.35 at the beginning of 2024. Since then, SRDX stock has decreased by 27.0% and is now trading at $26.52. View the best growth stocks for 2024 here .

When is Surmodics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our SRDX earnings forecast .

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) released its quarterly earnings results on Monday, February, 6th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.13. The business had revenue of $24.93 million for the quarter, compared to analyst estimates of $24.19 million. Surmodics had a net margin of 3.99% and a trailing twelve-month return on equity of 8.06%. During the same quarter in the prior year, the firm earned ($0.13) EPS.

What guidance has Surmodics issued on next quarter's earnings?

Surmodics updated its FY 2024 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of -1.170--0.870 for the period, compared to the consensus estimate of -1.160. The company issued revenue guidance of $113.0 million-$117.0 million, compared to the consensus revenue estimate of $119.3 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com . Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD) , Netflix (NFLX) , Exelixis (EXEL) , Intel (INTC) , NVIDIA (NVDA) , Tandem Diabetes Care (TNDM) , uniQure (QURE) , Sangamo Therapeutics (SGMO) , Abbott Laboratories (ABT) and Dynavax Technologies (DVAX) .

Who are Surmodics' major shareholders?

Surmodics' stock is owned by a number of retail and institutional investors. Top institutional investors include Salem Investment Counselors Inc. (0.85%). Insiders that own company stock include Charles W Olson, Charles W Olson , David Dantzker , Gary R Maharaj , John D Manders , Jose H Bedoya , Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr. View institutional ownership trends .

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SRDX

Surmodics (SRDX) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Free SRDX Stock Alerts

$26.52

-0.08 (-0.30%)

(As of 04/17/2024 ET)

Compare

Today's Range: $26.39
▼
$26.73
50-Day Range: $26.42
▼
$34.08
52-Week Range: $16.79
▼
$39.41

Volume: 443,034 shs
Average Volume: 72,990 shs
Market Capitalization: $377.64 million

P/E Ratio: 69.79
Dividend Yield: N/A
Price Target: $59.00

Get Surmodics alerts:

Surmodics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 122.5% Upside
$59.00 Price Target
Short Interest: Bearish
3.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.52
Upright™ Environmental Score
News Sentiment: 0.40
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.90) to ($0.02) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.12 out of 5 stars

Medical Sector

128th out of 913 stocks

Surgical & Medical Instruments Industry

22nd out of 89 stocks

3.5

Analyst's Opinion

Consensus Rating
Surmodics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Surmodics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.28% of the float of Surmodics has been sold short.
Short Interest Ratio / Days to Cover
Surmodics has a short interest ratio ("days to cover") of 9.8.
Change versus previous month
Short interest in Surmodics has recently increased by 1.34%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Surmodics does not currently pay a dividend.
Dividend Growth
Surmodics does not have a long track record of dividend growth.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Surmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Surmodics is -2.52.

2.4

News and Social Media Coverage

News Sentiment
Surmodics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Surmodics this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for SRDX on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Surmodics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Surmodics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.90% of the stock of Surmodics is held by insiders.
Percentage Held by Institutions
96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Surmodics are expected to grow in the coming year, from ($0.90) to ($0.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Surmodics is 69.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.98.
Price to Earnings Ratio vs. Sector
The P/E ratio of Surmodics is 69.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 270.63.
Price to Book Value per Share Ratio
Surmodics has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About Surmodics Stock (NASDAQ:SRDX)

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

SRDX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SRDX Stock News Headlines

April 17, 2024 | finance.yahoo.com

Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know

April 17, 2024 | americanbankingnews.com

Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

April 13, 2024 | finance.yahoo.com

Investors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three years

April 12, 2024 | americanbankingnews.com

Surmodics, Inc. to Post Q1 2025 Earnings of ($0.23) Per Share, Zacks Research Forecasts (NASDAQ:SRDX)

April 11, 2024 | americanbankingnews.com

Surmodics' (SRDX) Buy Rating Reiterated at Needham & Company LLC

April 11, 2024 | americanbankingnews.com

Surmodics, Inc. Expected to Earn Q4 2025 Earnings of $0.66 Per Share (NASDAQ:SRDX)

April 10, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

March 23, 2024 | finance.yahoo.com

Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?

March 2, 2024 | finance.yahoo.com

Are Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?

February 27, 2024 | businesswire.com

Surmodics to Participate in Upcoming Investor Conferences in March and April

February 6, 2024 | ca.finance.yahoo.com

SYK Jun 2024 290.000 put

February 4, 2024 | finance.yahoo.com

Here's What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter Results

February 2, 2024 | finance.yahoo.com

Here's Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Pay Packet

February 2, 2024 | finance.yahoo.com

Surmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call Transcript

February 2, 2024 | finance.yahoo.com

Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View

February 1, 2024 | marketwatch.com

Surmodics Shares Decline 10% on Investors' Lofty Expectations for SurVeil

February 1, 2024 | finance.yahoo.com

Surmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024

February 1, 2024 | msn.com

Surmodics beats top-line and bottom-line estimates; updates FY24 outlook

February 1, 2024 | finance.yahoo.com

SurModics (SRDX) Reports Break-Even Earnings for Q1

February 1, 2024 | finance.yahoo.com

SurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

February 1, 2024 | finance.yahoo.com

Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

January 31, 2024 | benzinga.com

A Preview Of Surmodics's Earnings

January 22, 2024 | finance.yahoo.com

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

January 16, 2024 | finance.yahoo.com

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

January 10, 2024 | finance.yahoo.com

Returns Are Gaining Momentum At Surmodics (NASDAQ:SRDX)

See More Headlines

Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/06/2023
Today: 4/17/2024
Next Earnings (Estimated): 4/24/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:SRDX
CUSIP: 86887310
CIK: 924717
Web: www.surmodics.com
Phone: (952) 500-7000
Fax: 952-500-7001
Employees: 376
Year Founded: 1979

Price Target and Rating

Average Stock Price Target: $59.00
High Stock Price Target: $71.00
Low Stock Price Target: $47.00
Potential Upside/Downside: +122.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.38
Trailing P/E Ratio: 69.79
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,540,000.00
Net Margins: 3.99%
Pretax Margin: 7.07%
Return on Equity: 8.06%
Return on Assets: 5.11%

Debt

Debt-to-Equity Ratio: 0.24
Current Ratio: 4.84
Quick Ratio: 3.97

Sales & Book Value

Annual Sales: $138.20 million
Price / Sales: 2.73
Cash Flow: $0.79 per share
Price / Cash Flow: 33.69
Book Value: $8.48 per share
Price / Book: 3.13

Miscellaneous

Outstanding Shares: 14,236,000
Free Float: 12,969,000
Market Cap: $377.54 million
Optionable: Optionable
Beta: 1.01

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Gary R. Maharaj (Age 61)
CEO, President & Director
Comp: $1.33M
Mr. Timothy J. Arens (Age 57)
Senior VP of Finance & Information Technology and CFO
Comp: $645.3k
Mr. Gordon S. Weber (Age 61)
Senior VP of Legal, General Counsel & Secretary
Comp: $602.84k
Mr. Charles W. Olson (Age 60)
Senior VP & President of Medical Device Coatings
Comp: $618.47k
Ms. Teryl L. W. Sides (Age 54)
Senior VP & President of Vascular Interventions
Comp: $744.38k
Mr. John D. Manders (Age 43)
Corporate Controller, VP of Finance & Principal Accounting Officer
Mr. Joseph J. Stich (Age 59)
Senior VP of Human Resources & President of In Vitro Diagnostics
Comp: $570.92k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SRDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings or view top-rated stocks.
What is Surmodics' stock price target for 2024?: 2 equities research analysts have issued twelve-month target prices for Surmodics' stock. Their SRDX share price targets range from $47.00 to $71.00. On average, they expect the company's stock price to reach $59.00 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price.
View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts.
How have SRDX shares performed in 2024?: Surmodics' stock was trading at $36.35 at the beginning of 2024. Since then, SRDX stock has decreased by 27.0% and is now trading at $26.52.
View the best growth stocks for 2024 here.
When is Surmodics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our SRDX earnings forecast.
How were Surmodics' earnings last quarter?: Surmodics, Inc. (NASDAQ:SRDX) released its quarterly earnings results on Monday, February, 6th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.13. The business had revenue of $24.93 million for the quarter, compared to analyst estimates of $24.19 million. Surmodics had a net margin of 3.99% and a trailing twelve-month return on equity of 8.06%. During the same quarter in the prior year, the firm earned ($0.13) EPS.
What guidance has Surmodics issued on next quarter's earnings?: Surmodics updated its FY 2024 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of -1.170--0.870 for the period, compared to the consensus estimate of -1.160. The company issued revenue guidance of $113.0 million-$117.0 million, compared to the consensus revenue estimate of $119.3 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?: 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.
What other stocks do shareholders of Surmodics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).
Who are Surmodics' major shareholders?: Surmodics' stock is owned by a number of retail and institutional investors. Top institutional investors include Salem Investment Counselors Inc. (0.85%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends.
How do I buy shares of Surmodics?: Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRDX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Surmodics (SRDX) Stock Price, News & Analysis

Surmodics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Surmodics Stock (NASDAQ:SRDX)

SRDX Stock Price History

SRDX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

SRDX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™